Ann: Compelling 85% Success Rate Remplir Study now published, page-8

Excuse me for stating obvious things, but the importance of peer-reviewed publication in a company that is looking to increase sales via KOL's in Australia particularly and possibly the US come early 2025 - though once again I am very pleasantly surprised by the confidence of this statement that mirrors previous strong convictions on sales on a product that is not even FDA approved yet:

"Top-line resultsfrom US FDA Remplir nerve repair study are expected in Q3 CY24, and Orthocell remains on schedule to submit its US 510(K) market authorisation application in Q4 CY24 with progression into sales soon thereafter."

THis is quite brazen guidance for a bio-tech awaiting approval. I reckon OCC has another BioHorizons/Henry Schein type deal in the wings for Remplir, to be using such forthright language about about sales there after.

"Publication will likely significantly raise the profile of Remplir with potential partners, practitioners and patients where the Company hasthe potential to become the leading device in the US in an addressable market estimated to be worth more than US$1.1 billion per annum."

Indeed....